Business Standard

Ranitidine cancer threat: Expect more clarity on products in coming weeks

Ranitidine sales account for 2 per cent of Strides sales and 6 per cent of its profit after tax

Ranitidine cancer threat: Expect more clarity on products in coming weeks
Premium

Sohini Das Mumbai
With the Australian drug regulator allowing sale of antacid ranitidine made by Strides Pharma, analysts say clarity will emerge in the ensuing weeks as most companies would have submitted their test results to the regulators.
 
In September, several companies, including British drugmajor GlaxoSmithKline Pharma (GSK), Hyderabad-based Dr Reddy’s Laboratories (DRL) had withdrawn their ranitidine products from the markets after the US Food and Drug Administration (USFDA) raising concerns over the presence of a cancer-causing substance in some ranitidine products.
 
Following this, ranitidine manufacturers in different countries (including the US, the EU, and India) were asked by the respective

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 27 2019 | 9:58 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com